Rehabilitation for a child with recalcitrant anti-N-methyl-D-aspartate receptor encephalitis: Case report and literature review

研究成果: Article

11 引文 (Scopus)

摘要

Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is a newly recognized, potentially fatal, but treatable autoimmune disease. Good outcome predictors include milder severity of symptoms, no need for intensive care unit admission, early aggressive immunotherapy, and prompt tumor removal. We report a case of a young girl aged 3 years 2 months and diagnosed as recalcitrant anti-NMDA receptor encephalitis without any underlying neoplasm. The patient had initial symptoms of behavioral changes that progressed to generalized choreoathetosis and orofacial dyskinesia, which resulted in 6 months of hospitalization in the pediatric intensive care unit. One year after initial onset of the disease, she had only achieved the developmental age of an infant aged 6–8 months in terms of gross and fine motor skills, but she resumed total independence in activities of daily living after receiving extensive immunotherapy and 28 months of rehabilitation. Our brief review will help clinical practitioners become more familiar with this disease and the unique rehabilitation programs.

原文English
頁(從 - 到)2263-2267
頁數5
期刊Neuropsychiatric Disease and Treatment
10
DOIs
出版狀態Published - 2014 十一月 24

指紋

Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Encephalitis
Immunotherapy
Rehabilitation
Behavioral Symptoms
Pediatric Intensive Care Units
Motor Skills
Dyskinesias
Activities of Daily Living
Autoimmune Diseases
Intensive Care Units
Neoplasms
Hospitalization
aspartic acid receptor

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

引用此文

@article{de545b170f1c49b09d7745a2c24ae371,
title = "Rehabilitation for a child with recalcitrant anti-N-methyl-D-aspartate receptor encephalitis: Case report and literature review",
abstract = "Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is a newly recognized, potentially fatal, but treatable autoimmune disease. Good outcome predictors include milder severity of symptoms, no need for intensive care unit admission, early aggressive immunotherapy, and prompt tumor removal. We report a case of a young girl aged 3 years 2 months and diagnosed as recalcitrant anti-NMDA receptor encephalitis without any underlying neoplasm. The patient had initial symptoms of behavioral changes that progressed to generalized choreoathetosis and orofacial dyskinesia, which resulted in 6 months of hospitalization in the pediatric intensive care unit. One year after initial onset of the disease, she had only achieved the developmental age of an infant aged 6–8 months in terms of gross and fine motor skills, but she resumed total independence in activities of daily living after receiving extensive immunotherapy and 28 months of rehabilitation. Our brief review will help clinical practitioners become more familiar with this disease and the unique rehabilitation programs.",
author = "Guo, {Yao Hong} and Kuan, {Ta Shen} and Hsieh, {Pei Chun} and Lien, {Wei Chih} and Chang, {Chun Kai} and Lin, {Yu Ching}",
year = "2014",
month = "11",
day = "24",
doi = "10.2147/NDT.S74205",
language = "English",
volume = "10",
pages = "2263--2267",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Rehabilitation for a child with recalcitrant anti-N-methyl-D-aspartate receptor encephalitis

T2 - Case report and literature review

AU - Guo, Yao Hong

AU - Kuan, Ta Shen

AU - Hsieh, Pei Chun

AU - Lien, Wei Chih

AU - Chang, Chun Kai

AU - Lin, Yu Ching

PY - 2014/11/24

Y1 - 2014/11/24

N2 - Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is a newly recognized, potentially fatal, but treatable autoimmune disease. Good outcome predictors include milder severity of symptoms, no need for intensive care unit admission, early aggressive immunotherapy, and prompt tumor removal. We report a case of a young girl aged 3 years 2 months and diagnosed as recalcitrant anti-NMDA receptor encephalitis without any underlying neoplasm. The patient had initial symptoms of behavioral changes that progressed to generalized choreoathetosis and orofacial dyskinesia, which resulted in 6 months of hospitalization in the pediatric intensive care unit. One year after initial onset of the disease, she had only achieved the developmental age of an infant aged 6–8 months in terms of gross and fine motor skills, but she resumed total independence in activities of daily living after receiving extensive immunotherapy and 28 months of rehabilitation. Our brief review will help clinical practitioners become more familiar with this disease and the unique rehabilitation programs.

AB - Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is a newly recognized, potentially fatal, but treatable autoimmune disease. Good outcome predictors include milder severity of symptoms, no need for intensive care unit admission, early aggressive immunotherapy, and prompt tumor removal. We report a case of a young girl aged 3 years 2 months and diagnosed as recalcitrant anti-NMDA receptor encephalitis without any underlying neoplasm. The patient had initial symptoms of behavioral changes that progressed to generalized choreoathetosis and orofacial dyskinesia, which resulted in 6 months of hospitalization in the pediatric intensive care unit. One year after initial onset of the disease, she had only achieved the developmental age of an infant aged 6–8 months in terms of gross and fine motor skills, but she resumed total independence in activities of daily living after receiving extensive immunotherapy and 28 months of rehabilitation. Our brief review will help clinical practitioners become more familiar with this disease and the unique rehabilitation programs.

UR - http://www.scopus.com/inward/record.url?scp=84912105814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912105814&partnerID=8YFLogxK

U2 - 10.2147/NDT.S74205

DO - 10.2147/NDT.S74205

M3 - Article

AN - SCOPUS:84912105814

VL - 10

SP - 2263

EP - 2267

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -